Changes to NICE influenza treatment guidance

NICE has updated its guidance on the treatment of influenza following a review of the use of amantadine, oseltamivir and zanamivir.

The revised guidance includes three key changes:

  • The addition of people with chronic liver disease or chronic neurological conditions to the list of ‘at risk' groups.*
  • The recommendation that zanamivir be considered as a treatment option for children aged five to 12 years in ‘at risk' groups provided that influenza is circulating and they can start treatment within 36 hours of first symptoms.
  • The recommendation that oseltamivir and zanamivir are now treatment options for ‘at-risk' people in long-term residential or nursing homes during localised outbreaks (when influenza is not circulating), if there is a high level of certainty that the causative agent is influenza.

*Other at-risk groups defined in the guidance include those with chronic respiratory, heart or renal disease or diabetes mellitus, those aged 65 years or over and those who may be immunosuppressed.

A summary of the new guidance is available at To read the full guidance visit the NICE website.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Close-up image of a COVID-19 antibody

Suspending methotrexate therapy shown to improve COVID booster response

Findings from a recent study showed that a two-week...